Community Pharmacies

Debate between James Naish and Rachel Gilmour

Tuesday 2nd June 2026 Westminster Hall

[Rachel Gilmour]

I assure the hon. Lady that some of the most frustrating conversations I have are with my local ICBs. Properly resourced pharmacies could release a staggering 51 million primary care appointments through an expanded Pharmacy First service, prevention services and a greater role in managing long-term conditions. That is 51 million appointments freed up in general practice, allowing more people to escape the infamous 8 am scramble. Pharmacies often meet people where they are, offering more accessible services to those who might not otherwise engage with the health service at all. They are arguably the most accessible arm of the NHS.

[James Naish (Rushcliffe) (Lab)]

I have been fortunate to have a pathfinder within the independent prescribing programme in my constituency. Its data shows that only 5% of patients who use the independent prescribing pathway need to be referred to their GP, so it is exactly as she says: there are huge savings to be made. I must push the Minister, because Community Pharmacy England has said that it is

“not persuaded that sufficient investment is being made to enable the full and effective introduction of independent prescribing.”

Does the hon. Lady agree that the Minister should look at that carefully to make sure that we are getting as much as we can out of community pharmacy?

[Rachel Gilmour]

I shall come to just that point in a minute. This sounds strange now, but I am going to say it: take obesity, for example. One in three people in the UK are currently classified as obese. Obesity is estimated to cost the NHS over £11.4 billion a year, with wider societal costs to the tune of £74 billion a year. Community pharmacies are ideally placed to provide wraparound support for those prescribed weight-loss medicines as part of an NHS-commissioned service, but they need the resources and the commissioning framework to do so.

There is one aspect of this debate that receives insufficient attention, and I want to raise it briefly. The ongoing situation in the middle east has hit the pharmaceutical supply chain as much as any other sector. There were a record 219 price concessions announced for community pharmacies in May alone, with further negotiations still ongoing. The cost of medicines has risen sharply. I understand that some cancer drugs have reportedly seen elevenfold increases. Crucially, medicine shortages and record-high price concessions reflect an instability in the supply chain that is being intensified by geopolitical pressures. I put it to the Government that the growing medicine supply crisis poses serious risks to Britain’s preparedness and resilience.